Discovery of Novel Benzimidazole Resistance Mechanisms
新型苯并咪唑耐药机制的发现
基本信息
- 批准号:10895749
- 负责人:
- 金额:$ 71.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAlbendazoleAllelesAnthelminticsBiological AssayCRISPR/Cas technologyCaenorhabditis elegansCollaborationsCommunitiesDrug DesignDrug TargetingEarly DiagnosisEconomic BurdenEnzymesEvolutionFarmFutureGenesGeneticGenetic CrossesGenomeGenomicsGoalsGrowthHaemonchusHealthHelminthsHookwormsHumanKnowledgeLaboratoriesLongevityMeasuresMedicineModelingMolecularMonitorMorbidity - disease rateNematodaParasite resistanceParasitesParasitic nematodePersonsPharmaceutical PreparationsPhenotypePhylogenetic AnalysisPoisoningPopulationPredispositionProductionProteinsResearchResearch PersonnelResistanceResourcesRuminantsSamplingSoilStructural BiologistTestingTherapeuticTimeTissuesTransgenic AnimalsTranslatingTubulin InteractionVeterinary MedicineX Chromosomebenzimidazolebenzimidazole resistancebeta Tubulindisability-adjusted life yearsexperimental studyfitnessfitness testfollow-upgamma Tubulingene discoverygenetic approachgenome editinggenome-widemortalitynoveloffspringpathogenprogramsresistance alleleresistance generesistance mechanismsuccesstransmission process
项目摘要
Project summary:
Parasitic nematodes impose a massive health and economic burden across much of the developing world,
infecting over one billion people worldwide. The morbidity and mortality inflicted by these devastating
pathogens is partly curtailed by mass drug administration (MDA) programs that depend on the continued
efficacy of a limited portfolio of anthelmintic drugs. Benzimidazole (BZ) compounds are a widely used class of
broad-spectrum anthelmintics that are an indispensable component of this limited chemotherapeutic arsenal.
The prospects of BZ resistance pose a serious threat to the future success of nematode control programs.
These prospects have been realized in the veterinary domain following intensive BZ use and are predicted to
materialize in human medicine with increased selection caused by expanded MDA. Early detection of
resistance-associated alleles in nematode parasite populations is essential to the goal of slowing anthelmintic
resistance and extending the lifespan of this critical drug class. Based on research in the free-living nematode
Caenorhabditis elegans from thirty years ago, parasitic nematode researchers focus on one BZ target, a
nematode-specific beta-tubulin. Despite this knowledge, it is still a complete mystery (1) whether any alleles
cause resistance (i.e. go beyond correlation), (2) the nematode tissues that are sensitive to BZ poisoning,
and (3) the drug-target interactions that cause resistance. In Haemonchus contortus, we have collected both
validated sensitive and resistance samples, and longitudinal samples where resistance has developed over
time. These samples are not available in any human parasitic nematode species. Using quantitative
resistance assays on these resources, we have shown that BZ resistance goes well beyond this single beta-
tubulin target. However, we do not know these independent resistance mechanisms in C. elegans or parasite
species. In Aim 1, we will test explicitly whether alleles correlated with resistance in parasites actually cause
resistance, test the fitness effects of these alleles, identify the tissues targeted by BZ, and characterize the
molecular mechanism for how beta-tubulin in affected by benzimidazoles. In Aim 2, we will discover beta-
tubulin independent mechanisms of resistance using the tractable C. elegans model nematode. In Aim 3, we
will expand our results to H. contortus where genomic and validated strain resources enable discoveries of
conserved resistance mechanisms. It is not possible in any parasitic nematode species to accomplish these
goals. New discoveries are possible only through this interplay between the model nematode C. elegans and
the tractable veterinary parasitic nematode H. contortus. Our results will have direct impacts on how
treatments are administered and resistance is monitored in human parasitic nematodes.
项目概要:
寄生线虫给许多发展中国家带来了巨大的健康和经济负担,
感染了全球超过十亿人这些毁灭性的疾病造成的发病率和死亡率
大规模药物管理(MDA)计划部分减少了病原体,这些计划依赖于持续的
有限的驱虫药组合的有效性。苯并咪唑(BZ)化合物是一类广泛使用的化合物,
广谱驱虫药是这种有限的化学治疗武器库的不可或缺的组成部分。
BZ抗性的前景对线虫防治计划的未来成功构成严重威胁。
这些前景已经在兽医领域实现了密集使用BZ,预计
在人类医学中实现,增加了由扩展的MDA引起的选择。早期发现
线虫寄生虫种群中的抗性相关等位基因对于减缓驱虫药的目标是必不可少的。
耐药性和延长这类关键药物的寿命。基于对自由生活的线虫的研究
从三十年前的秀丽隐杆线虫开始,寄生线虫研究人员专注于一个BZ目标,
线虫特异性β-微管蛋白。尽管有这些知识,它仍然是一个完全的谜(1)是否有任何等位基因
引起抗性(即超越相关性),(2)对BZ中毒敏感的线虫组织,
以及(3)引起耐药性的药物-靶标相互作用。在捻转血矛线虫中,
经验证的敏感和耐药性样品,以及耐药性已发展超过
时间这些样本在任何人类寄生线虫种属中均不可用。使用定量
在这些资源上的抗性测定中,我们已经表明BZ抗性远远超出了这种单一的β-
微管蛋白靶点然而,我们并不知道C中这些独立的耐药机制。线虫或寄生虫
物种在目标1中,我们将明确测试与寄生虫抗性相关的等位基因是否真的导致了
抗性,测试这些等位基因的适合性效应,鉴定BZ靶向的组织,并表征
β-微管蛋白如何受苯并咪唑类影响的分子机制。在目标2中,我们将发现beta-
微管蛋白独立的耐药机制使用易处理的C.线虫模式线虫在目标3中,我们
将结果推广到H.基因组和经验证的菌株资源能够发现
保守的抗性机制。在任何寄生线虫物种中都不可能实现这些
目标.只有通过模式线虫C.线虫和
兽用寄生线虫H.扭曲我们的研究结果将直接影响到
施用治疗并监测人寄生线虫的抗性。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genomic signatures of selection associated with benzimidazole drug treatments in Haemonchus contortus field populations.
与捻转血矛线虫田间苯并咪唑药物治疗相关的选择的基因组特征。
- DOI:10.1016/j.ijpara.2022.07.004
- 发表时间:2022
- 期刊:
- 影响因子:4
- 作者:Wit,Janneke;Workentine,MatthewL;Redman,Elizabeth;Laing,Roz;Stevens,Lewis;Cotton,JamesA;Chaudhry,Umer;Ali,Qasim;Andersen,ErikC;Yeaman,Samuel;Wasmuth,JamesD;Gilleard,JohnS
- 通讯作者:Gilleard,JohnS
Natural variation in Caenorhabditis elegans responses to the anthelmintic emodepside.
- DOI:10.1016/j.ijpddr.2021.04.001
- 发表时间:2021-08
- 期刊:
- 影响因子:0
- 作者:Wit J;Rodriguez BC;Andersen EC
- 通讯作者:Andersen EC
Two novel loci underlie natural differences in Caenorhabditis elegans abamectin responses.
- DOI:10.1371/journal.ppat.1009297
- 发表时间:2021-03
- 期刊:
- 影响因子:6.7
- 作者:Evans KS;Wit J;Stevens L;Hahnel SR;Rodriguez B;Park G;Zamanian M;Brady SC;Chao E;Introcaso K;Tanny RE;Andersen EC
- 通讯作者:Andersen EC
The Caenorhabditis elegans and Haemonchus contortus beta-tubulin genes cannot substitute for loss of the Saccharomyces cerevisiae beta-tubulin gene.
- DOI:10.17912/micropub.biology.000411
- 发表时间:2021-06-30
- 期刊:
- 影响因子:0
- 作者:Gibson SB;Harper CS;Lackner LL;Andersen EC
- 通讯作者:Andersen EC
Molecular evidence of widespread benzimidazole drug resistance in Ancylostoma caninum from domestic dogs throughout the USA and discovery of a novel β-tubulin benzimidazole resistance mutation.
- DOI:10.1371/journal.ppat.1011146
- 发表时间:2023-03
- 期刊:
- 影响因子:6.7
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erik Christian Andersen其他文献
Erik Christian Andersen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Erik Christian Andersen', 18)}}的其他基金
Genetic and genomic tools for C. briggsae research
用于 C. briggsae 研究的遗传和基因组工具
- 批准号:
10371532 - 财政年份:2022
- 资助金额:
$ 71.14万 - 项目类别:
Genetic and genomic tools for C. briggsae research
用于 C. briggsae 研究的遗传和基因组工具
- 批准号:
10582658 - 财政年份:2022
- 资助金额:
$ 71.14万 - 项目类别:
Discovery of novel benzimidazole resistance mechanisms
发现新的苯并咪唑耐药机制
- 批准号:
10190824 - 财政年份:2020
- 资助金额:
$ 71.14万 - 项目类别:
Discovery of novel benzimidazole resistance mechanisms
发现新的苯并咪唑耐药机制
- 批准号:
10438771 - 财政年份:2020
- 资助金额:
$ 71.14万 - 项目类别:
Discovery of novel benzimidazole resistance mechanisms
发现新的苯并咪唑耐药机制
- 批准号:
10029488 - 财政年份:2020
- 资助金额:
$ 71.14万 - 项目类别:
Discovery of conserved molecular mechanisms underlying population-wide variation in toxin responses
发现人群毒素反应差异的保守分子机制
- 批准号:
10579336 - 财政年份:2019
- 资助金额:
$ 71.14万 - 项目类别:
Discovery of conserved molecular mechanisms underlying population-wide variation in toxin responses
发现人群毒素反应差异的保守分子机制
- 批准号:
10328239 - 财政年份:2019
- 资助金额:
$ 71.14万 - 项目类别:
Discovery of conserved molecular mechanisms underlying population-wide variation in toxin responses
发现人群毒素反应差异的保守分子机制
- 批准号:
10088449 - 财政年份:2019
- 资助金额:
$ 71.14万 - 项目类别:
Large scale nutrigenetics and genomics in a tractable metazoan model
易处理的后生动物模型中的大规模营养遗传学和基因组学
- 批准号:
9761523 - 财政年份:2017
- 资助金额:
$ 71.14万 - 项目类别:
Large scale nutrigenetics and genomics in a tractable metazoan model
易处理的后生动物模型中的大规模营养遗传学和基因组学
- 批准号:
9423155 - 财政年份:2017
- 资助金额:
$ 71.14万 - 项目类别:
相似国自然基金
Albendazole增强肿瘤免疫抑制黑素瘤的作用与机制研究
- 批准号:82003286
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
School versus community-based albendazole deworming for control of soil transmitted helminths in school-age children in the Philippines – a cluster randomised controlled trial
学校与社区阿苯达唑驱虫对比控制菲律宾学龄儿童的土壤传播蠕虫——一项整群随机对照试验
- 批准号:
nhmrc : 1139561 - 财政年份:2018
- 资助金额:
$ 71.14万 - 项目类别:
Project Grants
School versus community-based albendazole deworming for control of soil transmitted helminths in school-age children in the Philippines – a cluster randomised controlled trial
学校与社区阿苯达唑驱虫对比控制菲律宾学龄儿童的土壤传播蠕虫——一项整群随机对照试验
- 批准号:
nhmrc : GNT1139561 - 财政年份:2018
- 资助金额:
$ 71.14万 - 项目类别:
Project Grants
Liver cystic echinococcosis: pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)
肝囊型包虫病:新型单步经皮治疗程序(囊内阿苯达唑亚砜注射液)的临床前评估
- 批准号:
9072551 - 财政年份:2016
- 资助金额:
$ 71.14万 - 项目类别:
Liver cystic echinococcosis: pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)
肝囊型包虫病:新型单步经皮治疗程序(囊内阿苯达唑亚砜注射液)的临床前评估
- 批准号:
9237195 - 财政年份:2016
- 资助金额:
$ 71.14万 - 项目类别:
Liver cystic echinococcosis: pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)
肝囊型包虫病:新型单步经皮治疗程序(囊内阿苯达唑亚砜注射液)的临床前评估
- 批准号:
9433603 - 财政年份:2016
- 资助金额:
$ 71.14万 - 项目类别:
Combined Albendazole Plus Praziquantel in Subarachnoid NCC, DCC Application
阿苯达唑联合吡喹酮在蛛网膜下腔 NCC、DCC 中的应用
- 批准号:
9323836 - 财政年份:2015
- 资助金额:
$ 71.14万 - 项目类别:
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application
联合阿苯达唑和吡喹酮治疗蛛网膜下腔 NCC、CCC、铅应用
- 批准号:
9751405 - 财政年份:2015
- 资助金额:
$ 71.14万 - 项目类别:
Combined Albendazole Plus Praziquantel in Subarachnoid NCC, DCC Application
阿苯达唑联合吡喹酮在蛛网膜下腔 NCC、DCC 中的应用
- 批准号:
9752680 - 财政年份:2015
- 资助金额:
$ 71.14万 - 项目类别:
Combined Albendazole Plus Praziquantel in Subarachnoid NCC, DCC Application
阿苯达唑联合吡喹酮在蛛网膜下腔 NCC、DCC 中的应用
- 批准号:
9134890 - 财政年份:2015
- 资助金额:
$ 71.14万 - 项目类别:
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application
联合阿苯达唑和吡喹酮治疗蛛网膜下腔 NCC、CCC、铅应用
- 批准号:
9134908 - 财政年份:2015
- 资助金额:
$ 71.14万 - 项目类别: